OrbiMed has held the closing of its second healthcare royalty and credit opportunities Fund, OrbiMed Royalty Opportunities II, with USD924 million in commitments, including USD24 million from the General Partner.
Investors in the fund include a broad range of premier endowment, foundation, pension and other institutional investors.
Consistent with its predecessor, the new fund will acquire healthcare royalty streams and provide tailored debt capital solutions to healthcare companies and institutions worldwide. The Fund expects to commit between USD20 million to USD150 million per investment, with the ability to commit larger amounts in collaboration with other OrbiMed funds.
“OrbiMed is active across a broad range of worldwide healthcare investing, including royalty and credit opportunities, public equity, and private equity. Interest in this fund reflects the strong appeal of the OrbiMed strategy and our USD14 billion global platform,” says Samuel D Isaly, Managing Partner.
“We are grateful for strong support from the LP community, which made for an efficient fundraise that exceeded our target with just a single closing,” says W Carter Neild, a Partner at OrbiMed. “We are particularly excited to welcome a dozen leading medical research and healthcare institutions as investors. OrbiMed looks forward to a strategic, collaborative relationship with them going forward.”
"We offer structured capital solutions, including combinations of royalty, debt, and equity financing, that provide companies and institutions another tool to solve their capital needs while also bringing them into the OrbiMed family," says Tadd Wessel, a Managing Director at OrbiMed.
“We are a value-added partner for our portfolio companies, bringing OrbiMed’s substantial strategic and operational resources to help them grow successfully,” says Matthew Rizzo, a Managing Director at OrbiMed.
